Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients

R. G. Vincent, C. R. Mehta, R. D. Tucker, C. F. Mountain, M. Cohen, H. E. Wilson, C. Vogel

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Two hundred ten patients with advanced adenocarcinoma of the lung were entered into a two-arm randomized trail. Cytoxan + CCNU + methotrexate was compared to Adriamycin and procarbazine. The tumor response to CCM was significantly higher than the tumor response to Adriamycin and procarbazine. No significance existed between the two treatments with respect to survival. Initial performance status, weight loss prior to therapy, and response to therapy were all found to be significant prognostic factors. Median survival time relative to responders in both treatment groups was 31.7 weeks and 15.8 weeks for non-responders.

Original languageEnglish (US)
Pages (from-to)256-260
Number of pages5
JournalCancer
Volume46
Issue number2
DOIs
StatePublished - Jul 15 1980
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients'. Together they form a unique fingerprint.

  • Cite this